NCT05291533

Brief Summary

This study aims to assess acceptability and preliminary efficacy of an intervention being administered clinically, a virtual reality (VR) mindfulness program. It is hypothesized that patients will find VR mindfulness an acceptable intervention and that it will reduce symptoms of anxiety.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
29

participants targeted

Target at below P25 for not_applicable anxiety

Timeline
Completed

Started May 2022

Typical duration for not_applicable anxiety

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 2, 2022

Completed
20 days until next milestone

First Posted

Study publicly available on registry

March 22, 2022

Completed
2 months until next milestone

Study Start

First participant enrolled

May 6, 2022

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 18, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 18, 2023

Completed
Last Updated

April 23, 2024

Status Verified

April 1, 2024

Enrollment Period

1.3 years

First QC Date

March 2, 2022

Last Update Submit

April 22, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in composite score on Client Satisfaction Questionnaire-8 (CSQ-8; Attkisson & Zwick, 1982)

    An 8-item, empirically validated measure of satisfaction with a clinical program. Scores therefore range from 8 to 32, with lower values indicating lower satisfaction and higher values indicating higher satisfaction.

    Immediately after first intervention (use of VR) and at hospital discharge an average of 10 days later

Secondary Outcomes (3)

  • Mean change in Subject Units of Distress (SUDS) from pre- to post-VR

    Immediately before and after each intervention (use of VR), up to two times per week for duration of hospital stay (average 10 days)

  • Mean change in Subjective units of relaxation from pre-to post-VR

    Immediately before and after each intervention (use of VR), up to two times per week for duration of hospital stay (average 10 days)

  • Mean change in General Anxiety Disorder-7 (GAD-7; Spitzer et al., 2006) from baseline to discharge

    Immediately before first intervention (use of VR) and at hospital discharge an average of 10 days later

Study Arms (1)

Patients using VR Mindfulness Program

OTHER

Participants are inpatients on any NYP/WCM unit that use VR mindfulness programs; any patient referred for a psychological or neuropsychological evaluation by their treatment team will have the opportunity to complete the VR program. The study is seeking to evaluate the feasibility and preliminary efficacy of the VR mindfulness intervention.

Other: Virtual Reality (VR) Mindfulness Program

Interventions

The VR program combines immersive, 3D visuals and audio with mindfulness skills practice. The program is designed to train participants you to calm their bodied and minds and its use is designed to enhance mindfulness practice. VR is a platform that has been used for a variety of applications, including gaming, entertainment, education and training.

Patients using VR Mindfulness Program

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Referred to psychology/neuropsychology
  • Identified by treatment team for use of VR mindfulness intervention
  • Able to provide informed consent or assent
  • Patient is over the age of 18

You may not qualify if:

  • Has not engaged in VR mindfulness intervention.
  • Determination by clinical team that patient cannot or would not benefit from participation in VR.
  • Reasons may include history of severe motion sickness or seizures, history of destruction of property, visual disturbance, vertigo, and cognitive impairment, delirium, and current or past diagnosis of a psychotic disorder

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Weill Cornell Medicine

New York, New York, 10065, United States

Location

MeSH Terms

Conditions

Anxiety Disorders

Condition Hierarchy (Ancestors)

Mental Disorders

Study Officials

  • Michelle Pelcovitz

    Weill Cornell Psychiatry

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 2, 2022

First Posted

March 22, 2022

Study Start

May 6, 2022

Primary Completion

August 18, 2023

Study Completion

August 18, 2023

Last Updated

April 23, 2024

Record last verified: 2024-04

Data Sharing

IPD Sharing
Will not share

Locations